
Practical Elements of a Radiopharmaceutical Program: Findings from ASTRO's Safety White Paper
Despite the rapid advancements, there exists a gap in the integration of radiopharmaceutical therapy within radiation oncology practices. Many practices predominantly focus on conventional techniques, overlooking the potential benefits and advancements offered by the strategic incorporation of radiopharmaceuticals. This gap underscores the need for a critical examination and restructuring of existing practices to embrace the full spectrum of therapeutic possibilities in the realm of radiation oncology.
Radiation oncology, nuclear medicine, surgical subspecialities, endocrinology, medical oncology and other specialties all have roles to play in radiopharmaceutical therapy and this collective approach underscores the intricate interplay of various disciplines, ultimately culminating in a treatment modality that offers both precision and potential for improved patient outcomes. The radiation oncologist – often the authorized user – serves a critical role as both the specific disease expert and treatment modality expert. This activity presents the findings from ASTRO’s Radiopharmaceutical Therapy Safety White Paper, describing practical information on establishing and maintaining a radiopharmaceutical program in radiation oncology.
Topics:
- Establishing a Radiopharmaceutical Program
John G. Phillips, MD, MPH - Technical Requirements for Radiopharmaceutical Therapies
Jacqueline E. Zoberi, PhD, DABR, FAAPM - Collaborative Workflows for Radiopharmaceutical Therapy
Philipose G. Mulugeta, MD - Quality Management for Radiopharmaceutical Therapy
Ravi B. Patel, MD, PhD - Q and A
Full Panel
This activity is available from January 14, 2025, through 11:59 p.m. Eastern time on January 13, 2027.
This activity was originally recorded at the 2024 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, physicists, nurses, diagnostic radiologists, radiation therapists, dosimetrists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Implement the information presented in their own practice to establish a new radiopharmaceutical program.
- Determine the gaps in their own practice that currently limit their ability to deliver radiopharmaceuticals.
- Jacqueline Esthappan Zoberi, PhD, DABR, FAAPM, is employed by Washington University School of Medicine. Dr. Zoberi receives registration fee waivers for ASTRO Annual Meetings as an Annual Meeting speaker. Dr. Zoberi serves as Chair of the Education and Training Committee of Medical Physics for AAPM.
- John Phillips, MD, MPH, is employed by Tennessee Oncology. Dr. Phillips receives grant/research funding and compensation from Monteris. Dr. Phillips serves in an uncompensated role with OneOncology. Dr. Phillips is a member of the ASTRO MDQA and a Senior Editor on the ABR OLA committee.
- Philipose G. Mulugeta, MD, is employed by Penn Medicine.
- Ravi Bhasker Patel, MD, PhD, is employed by UPMC Hillman Cancer Center. Dr. Patel receives grant/research funding from Voximetry and the NIH. Dr. Patel receives salary support from Merck. Dr. Patel owns patents through the Wisconsin Alumni Research Foundation. Dr. Patel serves as Co-chair of the Skin Cancer Pathway Development Committee with Elsevier Clinical Pathways.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until January 13, 2027, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.